港股异动 | 和黄医药(00013)现涨超4% 公司启动索乐匹尼布治疗贫血II/III期研究注册阶段

智通财经03-25

智通财经APP获悉，和黄医药(00013)现涨超4%，截至发稿，涨4.4%，报27.3港元，成交额3064.61万港元。消息面上，和黄医药近日宣布，在中国启动一项索乐匹尼布治疗温抗体型自身免疫性溶血性贫血(wAIHA)成人患者的II/III期研究的注册阶段。在此之前，该研究的II期概念验证阶段取得了积极的数据，并与中国国家药品监督管理局进行了沟通。若研究取得积极结果，其数据有望用于支持于未来提交...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422539804?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-25 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422539804","market":"us","top_or_hot":-1,"title":"港股异动 | 和黄医药(00013)现涨超4% 公司启动索乐匹尼布治疗贫血II/III期研究注册阶段","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，和黄医药(00013)现涨超4%，截至发稿，涨4.4%，报27.3港元，成交额3064.61万港元。消息面上，和黄医药近日宣布，在中国启动一项索乐匹尼布治疗温抗体型自身免疫性溶血性贫血(wAIHA)成人患者的II/III期研究的注册阶段。在此之前，该研究的II期概念验证阶段取得了积极的数据，并与中国国家药品监督管理局进行了沟通。若研究取得积极结果，其数据有望用于支持于未来提交...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1091252.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 和黄医药(00013)现涨超4% 公司启动索乐匹尼布治疗贫血II/III期研究注册阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 和黄医药(00013)现涨超4% 公司启动索乐匹尼布治疗贫血II/III期研究注册阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-25 10:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1091252.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，和黄医药(00013)现涨超4%，截至发稿，涨4.4%，报27.3港元，成交额3064.61万港元。消息面上，和黄医药近日宣布，在中国启动一项索乐匹尼布治疗温抗体型自身免疫性溶血性贫血(wAIHA)成人患者的II/III期研究的注册阶段。在此之前，该研究的II期概念验证阶段取得了积极的数据，并与中国国家药品监督管理局进行了沟通。若研究取得积极结果，其数据有望用于支持于未来提交...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1091252.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1091252.html","article_id":"2422539804","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422539804","pubTimestamp":1711333825,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，和黄医药现涨超4%，截至发稿，涨4.4%，报27.3港元，成交额3064.61万港元。消息面上，和黄医药近日宣布，在中国启动一项索乐匹尼布治疗温抗体型自身免疫性溶血性贫血成人患者的II/III期研究的注册阶段。在此之前，该研究的II期概念验证阶段取得了积极的数据，并与中国国家药品监督管理局进行了沟通。若研究取得积极结果，其数据有望用于支持于未来提交新药上市申请。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4007":"制药","BK1587":"次新股","YINN":"三倍做多富时中国ETF-Direxion","BK4134":"信息科技咨询与其它服务","BK1588":"回港中概股","III":"信息服务","00013":"和黄医药","YANG":"三倍做空富时中国ETF-Direxion","BK4531":"中概回港概念","BK1191":"制药","HCM":"和黄医药","BK4585":"ETF&股票定投概念","07226":"XL二南方恒科"},"translate_title":"Hong Kong stock changes and Huang Medicine (00013) have now risen by more than 4%. The company started the registration stage of Phase II/III research on the treatment of anemia with Suo Le Pinib","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"07226":1,"HCM":1,"III":1,"YANG":1,"YINN":1},"content_text":"智通财经APP获悉，和黄医药(00013)现涨超4%，截至发稿，涨4.4%，报27.3港元，成交额3064.61万港元。消息面上，和黄医药近日宣布，在中国启动一项索乐匹尼布治疗温抗体型自身免疫性溶血性贫血(wAIHA)成人患者的II/III期研究的注册阶段。在此之前，该研究的II期概念验证阶段取得了积极的数据，并与中国国家药品监督管理局进行了沟通。若研究取得积极结果，其数据有望用于支持于未来提交新药上市申请。中信建投此前发布研报称，和黄医药发布2023年全年业绩，肿瘤/自免综合业务收入符合之前公司给出的4.5-5.5亿美金的目标，产品销售额同比增长28%，其中呋喹替尼在23年11月在美国上市，23年收入达1500万美金，同时今年有望在欧洲和日本获批并在海外进一步放量。2024年底阿斯利康有望递交赛沃替尼MET异常的泰瑞沙难治性非小细胞肺癌适应症，国际化进程进一步推进。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422539804"}